Center for Clinical and Nutritional Chemistry, School of Chemistry, University of the Punjab, Lahore, Pakistan.
Chemical Pathology Department, Combined Military Hospital (CMH), Lahore, Pakistan.
Front Immunol. 2024 Nov 13;15:1448408. doi: 10.3389/fimmu.2024.1448408. eCollection 2024.
Pakistan has been seriously affected by the COVID-19 pandemic, with numerous waves of infection. Using different vaccine and booster doses was a key component to control and combat this pandemic. This study aims to monitor the heterologous and homologous booster vaccination doses that generate immune responses in healthy adults after 9 months of vaccination.
In this cross-sectional, observational study a total of 173 samples were collected. Participants from both genders (Male and Female) between the ages of 18 to 25 years were enrolled for the study. Participants who had booster shots of homologous Sinopharm BBIBP CorV and heterologous Pfizer-BioNTech vaccines were included only, with the use of a Roche Cobas-e601 analyzer, the antibody titers in the blood serum were quantified by the ECLIA method. IBM SPSS 22 was utilized for descriptive statistical analysis and P< 0.05 was considered significant.
In this study the IgG antibody levels were measured against the full length of receptor binding domain (RBD) of the spike (S) protein. The mean antibody titer in the Pfizer group was 9764 ± 10976 U/mL and 5762 ± 4302 U/mL in the Sinopharm group. The Mean IgG antibody levels of the Pfizer-vaccinated group were significantly higher than the Sinopharm-vaccinated group (P=0.000, each). Comparing the Sinopharm BBIBP CorV booster dosage to the Pfizer booster, Pfizer BNT162b2demonstrated a stronger immune response. However, there were no immunological gender-specific significant differences. The administration of a third dosage of Pfizer BNT162b2 after two doses of BBIBP CorV.
The administration of a third dosage of Pfizer BNT162b2 after two doses of BBIBP-CorV is recommended to boost the humoral immune response in the general population while there was no gender-specific difference observed. More effectiveness can be attained by administering additional doses due to the antibody decay.
巴基斯坦深受 COVID-19 大流行的影响，经历了多波感染。使用不同的疫苗和加强针剂量是控制和抗击这一大流行病的关键组成部分。本研究旨在监测健康成年人接种疫苗 9 个月后，使用不同疫苗和加强针剂量产生的免疫反应。
在这项横断面观察性研究中，共采集了 173 个样本。研究纳入了年龄在 18 至 25 岁之间的男女参与者。仅纳入接受同源 Sinopharm BBIBP CorV 和异源 Pfizer-BioNTech 疫苗加强针的参与者，使用罗氏 Cobas-e601 分析仪，通过 ECLIA 法定量血清中的抗体滴度。使用 IBM SPSS 22 进行描述性统计分析，P<0.05 为差异有统计学意义。
本研究测量了针对刺突（S）蛋白全长受体结合域（RBD）的 IgG 抗体水平。在 Pfizer 组中的平均抗体滴度为 9764±10976 U/mL，在 Sinopharm 组中的平均抗体滴度为 5762±4302 U/mL。Pfizer 疫苗组的平均 IgG 抗体水平明显高于 Sinopharm 疫苗组（P=0.000，均）。与 Sinopharm BBIBP CorV 加强剂量相比，Pfizer BNT162b2 显示出更强的免疫反应。然而，免疫反应在性别方面没有显著差异。在接种两剂 BBIBP CorV 后，再接种第三剂 Pfizer BNT162b2，可增强体液免疫反应。
建议在接种两剂 BBIBP-CorV 后，再接种第三剂 Pfizer BNT162b2，以增强普通人群的体液免疫反应，而在性别方面没有观察到差异。由于抗体衰减，接种更多剂量可以获得更高的效果。
